News
Article
What We’re Reading: US Adults at Risk of Heart Disease; Youth Mental Health, Addiction Support; FDA Postpones Meeting on Next COVID Vaccine Strain
Author(s):
Research shows a high prevalence of cardiovascular-kidney-metabolic (CKM) syndrome among adults; tackling mental health and substance abuse nationwide; a delayed meeting allows for surveillance data collection to inform recommendations.
An Alarming 90% of US Adults at Risk of Heart Disease, Study Finds
Nearly 90% of US adults are at risk of developing heart disease, signaling a critical need for proactive health measures, according to NBC News. The research underscored the importance of identifying cardiovascular-kidney-metabolic syndrome, which encompasses various risk factors including obesity, diabetes, and kidney disease, and called for early detection and aggressive intervention to curb the rising tide of cardiovascular complications. With lifestyle modifications and timely medical attention, individuals can mitigate their risk and safeguard against potentially devastating heart-related ailments, according to the study.
Biden Administration Commits $46.8 Million to Youth Mental Health, Addiction Support
The HHS in collaboration with the Substance Abuse and Mental Health Administration (SAMHSA), has allocated $46.8 million toward initiatives aimed at enhancing youth mental health, expanding the behavioral health workforce, and improving access to culturally competent care, according to a press release. The Biden administration’s commitment to addressing the mental health crisis and opioid epidemic has underscored the urgency of these efforts, which align with SAMHSA's strategic priorities. These grants not only aim to advance suicide prevention and early intervention strategies, but also strengthen the integration of primary and behavioral health care, contributing significantly to nationwide efforts to combat mental health and substance use challenges.
FDA Postpones Advisory Committee Meeting to Discuss Next COVID Vaccine Strain
The FDA has rescheduled its Vaccines and Related Biological Products Advisory Committee meeting from May 16 to June 5 to ensure access to the latest surveillance data for selecting the strain or strains for the 2024-25 COVID vaccines, according to Cidrap. While current vaccines target the XBB.1.5 variant, the dominance of the JN.1 strain has prompted discussions on transitioning to a monovalent vaccine. However, concerns arise over emerging JN.1 offshoots like KP.2 with FLiRT mutations, raising questions about immune evasion and vaccine efficacy.
